Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Gross Margin (2023 - 2025)

ImmunityBio (IBRX) has disclosed Gross Margin for 3 consecutive years, with 99.0% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 100.0% to 99.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 99.34% through Dec 2025, down 66.0% year-over-year, with the annual reading at 99.34% for FY2025, 66.0% down from the prior year.
  • Gross Margin for Q4 2025 was 99.0% at ImmunityBio, roughly flat from 99.45% in the prior quarter.
  • The five-year high for Gross Margin was 100.0% in Q2 2023, with the low at 99.0% in Q4 2025.
  • Average Gross Margin over 3 years is 99.78%, with a median of 100.0% recorded in 2023.
  • The sharpest move saw Gross Margin changed 0bps in 2024, then tumbled -100bps in 2025.
  • Over 3 years, Gross Margin stood at 100.0% in 2023, then changed by 0bps to 100.0% in 2024, then fell by -1bps to 99.0% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 99.0%, 99.45%, and 99.49% for Q4 2025, Q3 2025, and Q2 2025 respectively.